Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012

Global Markets Direct, March 2012, Pages: 159

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).
- A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutic Products under Development, Key Players in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Overview, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics under Development by Companies
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Products under Development by Companies
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Amgen Inc.
Merck & Co., Inc.
Gamida Cell Ltd.
Bio-Path Holdings, Inc.
BioSante Pharmaceuticals, Inc.
Novartis AG
Cephalon, Inc.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Celgene Corporation
Incyte Corporation
AEterna Zentaris Inc.
Ariad Pharmaceuticals, Inc.
TopoTarget A/S
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Natco Pharma Limited
Simcere Pharmaceutical Group
Piramal Life Sciences Limited
SymBio Pharmaceuticals Limited
ViroStatics, srl
S-BIO Pte Ltd
Deciphera Pharmaceuticals, LLC
Stemline Therapeutics, Inc.
Onconova Therapeutics, Inc
Syndax Pharmaceuticals, Inc.
Globeimmune, Inc.
KaloBios Pharmaceuticals, Inc.
Aprea AB.
Targa Therapeutics Corp.
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
StemEx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bosutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP24534 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omapro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omapro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thymoglobulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Campath - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate + AraC + Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate + Recombinant Interferon Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alpha + Hydroxyurea + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Wellferon + Cytarabine + Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon alfa + ARA-C + Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa + ARA-C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Busulfan + Cyclophosphamide + Thymoglobulin + Cyclosporin + Methylprednisolone + Umbilical Cord Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 + Peg-Interferon-Alpha2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Interferon Alfa + Busulfan + Cytarabine + Hydroxyurea + Idarubicin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dactinomycin + Sargramostim + CHOP Regimen + Carmustine + Cytarabine + Daunorubicin Hydrochloride + Etoposide + Mercaptopurine + Methotrexate + Mitoxantrone Hydrochloride + Pegaspargase + Prednisone + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-Azacytidin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sprycel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Drug Profile Updates
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Discontinued Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Dormant Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Product Development Milestones
Featured News & Press Releases
Feb 15, 2012: ARIAD Announces Issuance Of Key US Patent On Ponatinib
Feb 07, 2012: Bio-Path Successfully Completes Second Cohort In Phase I Clinical Trial Liposomal Grb-2 In Leukemia
Jan 27, 2012: Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
Jan 12, 2012: Kedem Initiates Development Of Sublingual Anti-Cancer Drug, Gleevec
Jan 12, 2012: NICE Rejects Novartis's Gleevec For Treatment Of Chronic Myeloid Leukemia That Is Resistant To Standard-Dose Imitanib
Jan 12, 2012: NICE Rejects Bristol-Myers Squibb's Sprycel For Treatment Of Chronic Myeloid Leukemia That Is Resistant To Standard-Dose Imitanib
Dec 22, 2011: Penn State Researchers Identify Potential Drug Compound To Cure Leukemia
Dec 13, 2011: Bio-Path Presents Initial Data From Phase I Leukemia Clinical Study At 53rd Annual Meeting Of American Society Of Hematology
Dec 10, 2011: Celgene Presents Oral Azacitidine Phase I Study Results At ASH Annual Meeting
Nov 17, 2011: ARIAD Announces Interim Safety And Efficacy Data From Pivotal Ponatinib PACE Trial To Be Presented At Annual American Society of Hematology Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2012
Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Bristol-Myers Squibb Company, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Abbott Laboratories, H1 2012
Amgen Inc., H1 2012
Merck & Co., Inc., H1 2012
Gamida Cell Ltd., H1 2012
Bio-Path Holdings, Inc., H1 2012
BioSante Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
Cephalon, Inc., H1 2012
Nippon Shinyaku Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Celgene Corporation, H1 2012
Incyte Corporation, H1 2012
AEterna Zentaris Inc., H1 2012
Ariad Pharmaceuticals, Inc., H1 2012
TopoTarget A/S, H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
Synta Pharmaceuticals Corp., H1 2012
Natco Pharma Limited, H1 2012
Simcere Pharmaceutical Group, H1 2012
Piramal Life Sciences Limited, H1 2012
SymBio Pharmaceuticals Limited, H1 2012
ViroStatics, srl, H1 2012
S-BIO Pte Ltd, H1 2012
Deciphera Pharmaceuticals, LLC, H1 2012
Stemline Therapeutics, Inc., H1 2012
Onconova Therapeutics, Inc, H1 2012
Syndax Pharmaceuticals, Inc., H1 2012
Globeimmune, Inc., H1 2012
KaloBios Pharmaceuticals, Inc., H1 2012
Aprea AB., H1 2012
Targa Therapeutics Corp., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Drug Profile Updates
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Discontinued Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Discontinued Products (Contd..1)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Discontinued Products (Contd..2)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..1)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..2)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..3)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..4)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..5)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..6)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..7)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..8)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics – Dormant Products (Contd..9)

List of Figures
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2012
Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Global Chronic Myeloid Leukemia Pipeline Capsule - 2013
• Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2013
• Global Chronic Myeloid Leukemia Drug Pipeline Capsule - 2012 Update
• Global Chronic Myeloid Leukemia Drug Pipeline Capsule - 2011
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012
• Chronic Myelocytic Leukemia (CML) - Pipeline Review, Q4 2010